Evidence‐based rationale for low dose nivolumab in critically ill patients with sepsis‐induced immunosuppression

MLA

Demy A. C. van denHaak, et al. “Evidence‐based Rationale for Low Dose Nivolumab in Critically Ill Patients with Sepsis‐induced Immunosuppression.” Clinical and Translational Science, vol. 16, no. 6, June 2023, pp. 978–86. EBSCOhost, https://doi.org/10.1111/cts.13503.

APA

Demy A. C. van denHaak, Leila‐Sophie Otten, Hans J. P. M. Koenen, Ruben L. Smeets, Berber Piet, Peter Pickkers, Matthijs Kox, & Rob ter Heine. (2023). Evidence‐based rationale for low dose nivolumab in critically ill patients with sepsis‐induced immunosuppression. Clinical and Translational Science, 16(6), 978–986. https://doi.org/10.1111/cts.13503

Chicago

Demy A. C. van denHaak, Leila‐Sophie Otten, Hans J. P. M. Koenen, Ruben L. Smeets, Berber Piet, Peter Pickkers, Matthijs Kox, and Rob ter Heine. 2023. “Evidence‐based Rationale for Low Dose Nivolumab in Critically Ill Patients with Sepsis‐induced Immunosuppression.” Clinical and Translational Science 16 (6): 978–86. doi:10.1111/cts.13503.